Conceptus, Inc. (NASDAQ:CPTS)
CAPS Rating:
The Company develops, manufactures and markets the Essure(r) permanent birth control system, an innovative and proprietary medical device for women.
Got Stock?
The Company develops, manufactures and markets the Essure(r) permanent birth control system, an innovative and proprietary medical device for women.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
i am an OB/GYN MD and with the movement of the Essure procedure into the office setting i expect to continue to see triple digit revenue growth quarter over quarter over the next 2-3 years.
Get ready for a leg up. Already missed the first $2 gain. Patient demand is increasing and docs are realizing Essure is better than Adiana. I wouldn't be surprised if they are bought (?JNJ).
Contrary to what the market thinks, this company is not dead. Give it 1 year and revenues and stock price will be up.